Login    Join free Add to favorites    中文
home > news > InflaRx announces appointment of Tony Gibney to its Board of Directors
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
InflaRx announces appointment of Tony Gibney to its Board of Directors

hits:533     Date:02/07/18
Jena, Germany, February 6, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing new therapeutics in the terminal complement space, today announced the addition of Tony Gibney to its Board of Directors. Mr. Gibney is a highly experienced life sciences-focused investment banker and has executed over 150 financings and M&A advisory transactions for US and European clients. Mr. Gibney's appointment was approved by InflaRx' shareholders at the extraordinary shareholder meeting held in Amsterdam, the Netherlands today.
 
Prof. Niels C. Riedemann, Chief Executive Officer of InflaRx, said: "I am very excited to have Tony join our Board. Having worked with Tony during our highly successful IPO in 2017, I know we will greatly benefit from his financial and corporate development expertise. With more than two decades of experience in life sciences investment banking, and with his incredible network in the industry, Tony will be a true asset to InflaRx as we grow the Company."
 
Tony Gibney, Board member of InflaRx, said: "I am pleased to have the opportunity to join the InflaRx' Board. I am impressed with the Company's achievements to date and excited about the potential of InflaRx' therapeutic programs. I look forward to contributing to the Company's continued success as it advances its development programs."
 
Tony Gibney was a life sciences-focused investment banker for 23 years. From 2009 through 2017, he served as a managing director and co-head of the biotechnology investment team for Leerink Partners LLC, where he was a senior leader of Leerink's biopharmaceutical investment banking franchise. At Leerink, Mr. Gibney had primary coverage responsibilities for selected East Coast biopharmaceutical and European pharmaceutical clients. From 1999 to 2009, he worked as a managing director at Merrill Lynch Inc. and executed a variety of significant financing and M&A transactions for various biotechnology companies. From 1993 to 1999, Mr. Gibney was an investment banker at Lehman Brothers in the firm's Healthcare Investment Banking Group. He graduated with distinction from Yale University in 1993 with a B.A. in History and Economics.
 
More information on InflaRx' Board is available at http://www.inflarx.de/Home/About-Inflarx/Board.html.
 
About InflaRx N.V.:
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol "IFRX." For further information please visit www.inflarx.com.
 
Contacts:
InflaRx N.V.

Prof. Dr. Niels C. Riedemann - CEO
Email: info[at]inflarx.de
Tel: +49-3641-508180
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙